Thermo Fisher opens Bioprocess Design Center in Hyderabad

Expands bioprocessing footprint across Asia

Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership

The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination

Pfizer’s therapy scores major win in Phase 3 trial for Hemophilia patients with inhibitors

HYMPAVZI’s safety profile was generally favorable

Groundbreaking study identifies 250 genes driving ME & long COVID

76 of 180 long COVID-associated genes also linked to ME

Takeda seals $1.2 billion oncology deal with Innovent Biologics

Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent

Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment

Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development

Bayer advances fight against rare kidney disease with new experimental drug

Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes

Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy

Bayer launches phase III trial testing Mirena for uterine condition with no treatments

NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer

Bayer reports promising results for low-dose pediatric MRI contrast agent

MRI is particularly valuable in pediatric care due to its non-invasive nature